AOLS — Aeolus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.02m
- -$0.39m
- $2.08m
Annual income statement for Aeolus Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2012 September 30th | 2013 September 30th | 2014 September 30th | 2015 September 30th | 2016 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.29 | 3.93 | 9.63 | 3.11 | 2.08 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 9.66 | 6.63 | 9.71 | 5.74 | 5.35 |
| Operating Profit | -2.37 | -2.7 | -0.08 | -2.63 | -3.27 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1.7 | -3.21 | -0.08 | -2.63 | -3.56 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.7 | -3.21 | -0.08 | -2.63 | -3.56 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.7 | -3.21 | -0.08 | -2.63 | -3.56 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -2.16 | -3.21 | -0.08 | -2.63 | -6.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.03 | -0.03 | -0.001 | -0.019 | -0.041 |
| Dividends per Share |